market-trends is the sole category represented across all 1 tracked stories. Anteris Technologies is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 5 original sources on average, compared with 4 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about 4D Medical
market-trends is the sole category represented across all 1 tracked stories. Anteris Technologies is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 5 original sources on average, compared with 4 for the broader beat in this window. The 6 average consequence score is above the beat benchmark of 5.7 in the same window. We currently track 1 Healthcare story that mention 4D Medical, all published on February 25, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 31 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering 4D Medical. Shared-story counts are live from our verified record — not editorial picks.
The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation.